1. Home
  2. WNEB vs ADAG Comparison

WNEB vs ADAG Comparison

Compare WNEB & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western New England Bancorp Inc.

WNEB

Western New England Bancorp Inc.

HOLD

Current Price

$14.10

Market Cap

264.8M

Sector

Finance

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.82

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNEB
ADAG
Founded
1853
2011
Country
United States
China
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.8M
254.4M
IPO Year
2001
2020

Fundamental Metrics

Financial Performance
Metric
WNEB
ADAG
Price
$14.10
$3.82
Analyst Decision
Buy
Strong Buy
Analyst Count
3
4
Target Price
$13.67
$8.25
AVG Volume (30 Days)
50.7K
366.1K
Earning Date
04-28-2026
04-01-2026
Dividend Yield
2.00%
N/A
EPS Growth
33.93
N/A
EPS
0.75
N/A
Revenue
$44,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.25
N/A
P/E Ratio
$18.61
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$1.44
52 Week High
$14.52
$4.75

Technical Indicators

Market Signals
Indicator
WNEB
ADAG
Relative Strength Index (RSI) 63.10 52.34
Support Level $13.60 $3.49
Resistance Level $14.47 $4.10
Average True Range (ATR) 0.31 0.23
MACD 0.00 -0.04
Stochastic Oscillator 62.37 67.44

Price Performance

Historical Comparison
WNEB
ADAG

About WNEB Western New England Bancorp Inc.

Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: